Novartis AG (NVS) Stock Holds Steady as White House Nears Drug Pricing Deal

Pharma giant Novartis sees its stock price hold firm—a rare feat of stability as Washington circles its biggest cash cows.

The Waiting Game

Investors aren't flinching. While headlines scream about impending government price negotiations, Novartis shares barely budge. The market's betting the Swiss titan's pipeline and global footprint can absorb the hit—or that the deal gets watered down into irrelevance.

Portfolio Armor

It's not just blind faith. Blockbuster drugs and a deep R&D bench create a buffer. The Street's calculus is simple: even trimmed margins on a massive revenue base still print money. It's the pharmaceutical version of 'too big to fail.'

The Real Cost

Forget the political theater. The real question isn't if prices get cut, but where those lost profits get clawed back. Hint: it won't be from executive bonuses or shareholder dividends. The math always finds a way—usually onto someone else's balance sheet.

So Novartis holds steady. A masterclass in corporate inertia, proving that in high-stakes pharma, sometimes just not collapsing is its own kind of victory. Another day, another dollar—just slightly more negotiated.

TLDR

• Novartis stock trades around $135.31 during market hours
• White House may announce a drug pricing deal with Novartis and Roche
• Agreement could provide tariff relief and regulatory certainty
• Novartis derives over 40% of revenue from the US market
• Investors watch policy clarity as pricing pressure remains central

Novartis AG (NVS) stock was trading at $135.31, up 0.21% during the US market session, as investors reacted to reports that the WHITE House is nearing a drug pricing agreement with the Swiss pharmaceutical giant.

Novartis AG, NVS

According to people familiar with the matter, the announcement could come as soon as Friday, marking a potential turning point in negotiations between the US administration and major global drugmakers.

The talks place Novartis alongside Roche Holding AG, with the possibility that other pharmaceutical companies could also be included. While details remain fluid, the development signals progress in efforts to reduce US prescription drug costs while easing trade-related uncertainty.

White House Push on Drug Prices

The TRUMP administration has made lowering drug prices a central policy objective, frequently highlighting the gap between US medicine costs and those in other high-income countries. Over the summer, President Donald Trump sent letters to 17 pharmaceutical companies demanding price reductions for a US government insurance program, alignment of US pricing with foreign markets, and participation in a Trump-branded direct-to-consumer platform.

The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis and Roche, further easing trade tensions with Switzerland after a standoff over tariffs https://t.co/0EuK0iOqUM

— Bloomberg (@business) December 17, 2025

In exchange, companies were offered multi-year relief from threatened tariffs and certain regulatory actions. Pfizer and AstraZeneca have already reached agreements under these terms, setting a precedent that markets now see as favorable for Novartis and Roche.

Trade Tensions and Tariff Relief

The reported talks come amid easing trade tensions between the US and Switzerland. Last month, Switzerland reached a preliminary agreement to lower tariffs on many goods to 15% from 39% after facing the highest levy imposed on any developed nation by the Trump administration. Pharmaceuticals were exempt from those tariffs, though Trump had warned of possible future duties.

A pricing deal with Novartis WOULD reduce uncertainty tied to those threats, offering clearer long-term visibility for the company’s US operations. Roche, through its Genentech unit, has also indicated a willingness to work with the administration to lower costs while protecting innovation incentives.

Novartis’ US Exposure and Strategy

The United States plays a critical role in Novartis’ revenue mix. The company generates about 41% of its sales from the US market, driven by blockbuster therapies such as heart failure drug Entresto and psoriasis treatment Cosentyx. Novartis reports earnings in US dollars, making US policy outcomes especially influential for investors.

To reinforce its commitment, Novartis has pledged to invest $23 billion in the US over the next five years. That includes domestic manufacturing expansion, highlighted by the recent groundbreaking of a North Carolina facility attended by CEO Vas Narasimhan and FDA Commissioner Marty Makary. The company has also announced plans for a direct-to-patient platform for Cosentyx, aligning with White House priorities.

Industry-Wide Implications

While Novartis and Roche appear close to a deal, many companies that received Trump’s letters have yet to announce agreements. These include AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Merck, Amgen, GSK, Sanofi, and Regeneron. The lack of clarity has kept pressure on the broader pharmaceutical sector, where pricing reform remains a persistent overhang.

Democrats have raised concerns over whether these confidential agreements will generate real savings for the US government. Questions persist around transparency and the long-term impact on innovation funding, an argument frequently raised by drugmakers.